• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Marinomed gets funding for development of Carragelose inhalation solution for the treatment of COVID-19 pneumonia

Marinomed Biotech has announced new funding from the Austrian Research Promotion Agency (FFG) for development of a Carragelose inhalation solution for COVID-19 pneumonia. The funding is part of the FFG’s “Emergency Call to research COVID-19 in the wake of the outbreak of SARS-CoV-2.”

Carragelose is a polymer derived from red seaweed that has shown activity against a range of viruses, including the common cold. Carragelose-based antiviral nasal sprays have been approved and are marketed in a number of countries in Europe and Asia, as well as in Canada.

The company plans to use the funding for a Phase 1 study in healthy volunteers followed by a proof of concept study conducted at the Medical University of Vienna to evaluate the effectiveness of the inhalation solution in patients with viral pneumonia. According to the company, a previous study conducted in 2014 demonstrated that treatment with Carragelose reduced the duration of symptoms by 3 days in patients infected with a coronavirus compared to placebo.

Marinomed Chief Scientific Officer Eva Prieschl-Grassauer said, “A causal therapy directly in the lungs can shorten the duration of the disease and thus hospitalization for patients suffering from viral pneumonia, reduce the number of patients in intensive care and thus bring enormous benefits for patients and the health system. . . . Due to the broad effectiveness of Carragelose, we are confident that we can also achieve good results with the current pandemic coronavirus.”

Read the Marinomed Biotech press release.

Share

published on April 28, 2020

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews